Further to that, we noted that high PCK2 expression resulted in reduced macrophage infiltration, particularly in M2 cells, which significantly improved patient overall survival, implying that PCK2 could become an immunotherapy target for M2 macrophages and improve the cumulative survival rate in HCC (Fig. 8B). This evidence concerns the gene PCK2 and hepatocellular carcinoma.